跳转到主内容

非常抱歉,我们不完全支持您的浏览器。如果您可以选择,请升级到较新版本或使用 Mozilla Firefox、Microsoft Edge、Google Chrome 或 Safari 14 或更高版本。如果您无法进行此操作且需要支持,请将您的反馈发送给我们。

全新设计的官网为您带来全新体验,期待您的反馈 在新的选项卡/窗口中打开

Elsevier
通过我们出版

Translational Immunology

Aim & scope

Translational Immunology is a major new suite of books in immunology, which cover both basic and clinical immunology. The series seeks to discuss and provide foundational content from bench to bedside in immunology.

The Series’ goal is to enhance knowledge, and present update on hot topics in the field of immunology; specifically, the series aims to translate results and recent findings of studies into clinical practice.

Written and edited by leading international scientists, the series is primarily intended for researchers, clinicians, and students in immunology at the graduate level and above, including those working in academic, corporate, or non-profit settings.

Translational Immunology

Its ethics mission is to enable global benefit sharing of advances in the field of immunology through the publication of foundational, consensus building content.

The Translational Immunology series seeks to provide wide coverage across areas of Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), which is one of main area of science without borders in Universal Scientific Education and Research Network (USERN). Possible subject areas covered by Series Volumes include: Autoimmunity, Allergy, Infection and Immunity, Inborn Errors of Immunity, Immunodeficiencies, AIDS, Immunopharmacology, Transplantation, Cancer Immunology, Immunotherapy, Neuroimmunology, Vaccination.

Audience

Researchers, clinicians, and students in the field of immunology at the graduate level and above, including those working in academic, corporate, or non-profit settings.

Secondary Markets

Immunologists, clinical immunologists and allergists, rheumatologists, haematologists and oncologists, and paediatricians.

Editor

Nima Rezaei

NR

Nima Rezaei

Professor

Tehran University

阅读更多有关 Nima Rezaei 的信息